The significant reduction in net loss and extended cash runway reduce near-term dilution risk. While no revenue was generated from collaborations, pipeline progress — especially in HBV and obesity — supports long-term value. Watch for interim data readouts in 2026 and potential partnership or out-licensing activity for ALG-055009.
Price Chart
Executive Summary
Aligos Therapeutics reported financial results for Q4 and full year 2025, showing a大幅 reduction in net loss from the prior year and ending 2025 with $77.8 million in cash, sufficient to fund operations into Q3 2026. The company highlighted progress in its HBV pipeline, including completion of enrollment in the HBeAg- cohort of the Phase 2 B-SUPREME trial for pevifoscorvir sodium and advancement of ALG-170675 into IND-enabling studies with partner Amoytop.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $24.2 million vs. $131.2 million in 2024, a 81.6% improvement.
- Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, up from $56.9 million a year earlier.
- Cash runway expected into Q3 2026.
- Completed enrollment in HBeAg- cohort of Phase 2 B-SUPREME study; HBeAg+ enrollment ongoing.
- Topline data from B-SUPREME trial expected in 2027.
- ALG-170675 advanced into IND-enabling studies with Amoytop funding development in China.
- Preclinical data show ALG-055009 combined with incretin agonists (semaglutide/tirzepatide) produced up to 40% body weight loss in mice.
- Appointed James Hassard as Chief Commercial Officer.
Financial Impact
Reduced annual net loss by $107 million YoY; R&D expenses slightly down despite advancing key programs. Positive cash flow impact from $60.2M gain on warrant revaluation, though non-recurring.
Risk Factors
- No product revenue; company remains pre-revenue with high dependence on clinical milestones.
- Cash runway only into Q3 2026, implying need for financing before year-end, likely dilutive.
- Forward-looking statements dominate; near-term catalysts are interim analyses, not topline data until 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250065 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $5.51 $6.77 | ▲ +22.87% | ▲ +21.65% | $4.65 (−15.61%) |
Jun 26, 2026 17w ago | 8-K | $5.43 $5.85 | ▲ +7.73% | ▲ +6.35% | $4.65 (−14.36%) |
May 27, 2026 21w ago | Press Release | $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $4.65 (−16.96%) |
Apr 16, 2026 27w ago | Press Release | $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $4.65 (−39.30%) |
Apr 14, 2026 28w ago | Press Release | $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $4.65 (−37.33%) |
Mar 5, 2026 33w ago | 8-K | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.65 (−30.18%) |
Mar 5, 2026 33w ago | Press Release | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.65 (−30.18%) |
Feb 28, 2026 34w ago | Institutional Cluster | $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $4.65 (−33.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers